KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBT (2017 - 2025)

Historic EBT for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to -$72.7 million.

  • Cardlytics' EBT rose 4994.35% to -$72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.8 million, marking a year-over-year increase of 5963.32%. This contributed to the annual value of -$189.3 million for FY2024, which is 4053.54% down from last year.
  • As of Q3 2025, Cardlytics' EBT stood at -$72.7 million, which was up 4994.35% from -$9.3 million recorded in Q2 2025.
  • Over the past 5 years, Cardlytics' EBT peaked at $33.0 million during Q1 2022, and registered a low of -$378.3 million during Q4 2022.
  • Moreover, its 5-year median value for EBT was -$24.0 million (2023), whereas its average is -$53.8 million.
  • Within the past 5 years, the most significant YoY rise in Cardlytics' EBT was 23270.94% (2022), while the steepest drop was 182029.54% (2022).
  • Quarter analysis of 5 years shows Cardlytics' EBT stood at -$19.7 million in 2021, then tumbled by 1820.3% to -$378.3 million in 2022, then skyrocketed by 73.34% to -$100.8 million in 2023, then surged by 84.54% to -$15.6 million in 2024, then tumbled by 366.18% to -$72.7 million in 2025.
  • Its EBT was -$72.7 million in Q3 2025, compared to -$9.3 million in Q2 2025 and -$13.3 million in Q1 2025.